clinical endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-12 and is reviewed periodically as new material appears.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Common matrix | Plasma or serum | Collected under controlled conditions |
| Primary method | Liquid chromatography–tandem mass spectrometry | Structural specificity |
| Alternative method | Immunoassay | Lower specificity, higher throughput |
| Reporting unit | ng/mL | Concentration in matrix |
| Key validation item | Selectivity | Interference from related peptides |
the equation reduces to the incompressible-flow form. The constant on the right-hand side is often called the Bernoulli constant and denoted b. For steady inviscid adiabatic flow with no additional sources or sinks of energy, b is constant along any given streamline. More generally, when b may vary along streamlines, it still proves a useful parameter, related to the "head" of the fluid (see below). When the change in Ψ can be ignored, a very useful form of this equation is:
NSAIDs (inhibit cyclooxygenase) and COX-2 selective inhibitors or coxibs Corticosteroids (inhibit phospholipase A2 production) Cyclopentenone prostaglandins may play a role in inhibiting inflammation Vitamin D3 and vitamin K2.
According to a 2010 report on co-authored by Miron, the annual savings on enforcement and incarceration costs from the legalization of drugs would amount to roughly $41.3 billion, with $25.7 billion being saved among the states and over $15.6 billion accrued for the federal government. Miron further estimated at least $46.7 billion in tax revenue based on rates comparable to those on tobacco and alcohol: $8.7 billion from marijuana, $32.6 billion from cocaine and heroin, and $5.4 billion from other drugs. Regarding economic arguments for legalization that make a comparison with alcohol, a 2013 study noted that the $14.6 billion in annual alcohol tax collected at the US federal and state levels represented less than 10% of the estimated $185 billion of alcohol-related health care, criminal justice and lost productivity costs.
=== Anion Exchange === Anion exchange separation methods are widely used in the purification of actinides and actinide bearing materials through the use of resin columns. The anionic actinide complexes are retained by anion exchange sites that are on the resin and neutral species pass through the column unretained. Then the retained species can be eluted from the column by conversion to a neutral complex, typically by changing the mobile phase passed through the resin bed. Anion exchange-based separations of actinides, while valued for their simplicity and widely used, tend to be time-consuming and are infrequently automated. Most are still dependent on gravity. Speeding up the flow of the mobile phase tends to introduce problems such as impurities and jeopardize future investigations. Hence, there is still a need for development of this technique to satisfy the nuclear forensic research priorities.
Sources: en.wikipedia.org
Income inequality has traditionally been low in Denmark. According to OECD figures, in 2000 Denmark had the lowest Gini coefficient of all countries. However, inequality has increased during the last decades. According to data from Statistics Denmark, the Gini coefficient for disposable income has increased from 22.1 in 1987 to 29.3 in 2017. The Danish Economic Council found in an analysis from 2016 that the increasing inequality in Denmark is due to several components: Pre-tax labour income is more unequally distributed today than before, capital income, which is generally less equally distributed than labour income, has increased as share of total income, and economic policy is less redistributive today, both because public income transfers play a smaller role today and because the tax system has become less progressive. In international comparisons, Denmark has a relatively equal income distribution. According to the CIA World Factbook, Denmark had the twentieth-lowest Gini coefficient (29.0) of 158 countries in 2016. According to data from Eurostat, Denmark was the EU country with the seventh-lowest Gini coefficient in 2017. Slovakia, Slovenia, Czechia, Finland, Belgium and the Netherlands had a lower Gini coefficient for disposable income than Denmark.
Biological machines are considered to be nanoscale devices (such as molecular proteins) in a living system that convert various forms of energy to mechanical work in order to drive crucial biological processes such as intracellular transport, muscle contractions, ATP generation and cell division.
Britain wanted to see an end to Spanish rule in South America and ultimately tap the monopoly of the important potential markets there. At the same time they wanted Spain as an ally to keep the balance of power in post-Napoleonic Europe. To fulfil this, Britain went covert in support of the Revolutionaries in South America. In a kind of private free enterprise going by the law, she sent men, financial and material support to help the insurgents fight against Spain. One of the most significant contributions were the British Legions, a volunteer unit that fought under Simón Bolívar. This force numbered upwards of 6,000 men – the majority of whom were composed of veterans of the Napoleonic Wars. In combat their greatest achievements were at Boyacá (1819), Carabobo (1821), Pichincha (1822) and Ayacucho (1824) which secured independence for Colombia, Venezuela, Ecuador and Peru from Spanish rule respectively. Bolívar described the Legions and all who served in them as "the saviours of my country". Many members of the Royal Navy also volunteered for the revolutionary forces. The most famous being Thomas Cochrane who reorganised the Chilean navy, most of whom were composed of Royal Navy veterans. Amongst many feats he captured the Spanish fortress of Valdivia in 1820; and in the same year he captured the flagship of the Spanish South American fleet, the Esmeralda, in the port of Callao. As well as helping Chile gain independence from Spain Cochrane did the same for Peru too by mounting an effective blockade and transporting troops.
Sources: en.wikipedia.org
In surgical praxis, after having emplaced the empty breast implants to the implant pockets, the plastic surgeon then filled each device with saline solution, and, because the required insertion-incisions are short and small, the resultant incision-scars will be smaller and shorter than the surgical scars usual to the long incisions required for inserting pre-filled, silicone-gel implants. When compared to the results achieved with a silicone-gel breast implant, the saline implant can yield acceptable results, of increased breast-size, smoother hemisphere-contour, and realistic texture; yet, it is likelier to cause cosmetic problems, such as the rippling and the wrinkling of the breast-envelope skin, accelerated lower breast pole stretch, and technical problems, such as the presence of the implant being noticeable to the eye and to the touch. The occurrence of such cosmetic problems is likelier in the case of the woman with very little breast tissue, and in the case of the woman who requires post-mastectomy breast reconstruction; thus, the silicone-gel implant is the technically superior prosthetic device for breast augmentation, and for breast reconstruction. In the case of the woman with much breast tissue, for whom sub-muscular emplacement is the recommended surgical approach, saline breast implants can produce an aesthetic result much like that afforded by silicone breast implants. Ultrasound examination and outcome studies have revealed that saline and silicone breast implants look and feel similar.
== EC numbers == Many serine/threonine protein kinases do not have their own individual EC numbers and use 2.7.11.1, "non-specific serine/threonine protein kinase". This entry is for any enzyme that phosphorylates proteins while converting ATP to ADP (i.e., ATP:protein phosphotransferases.) 2.7.11.37 "protein kinase" was the former generic placeholder and was split into several entries (including 2.7.11.1) in 2005. 2.7.11.70 "protamine kinase" was merged into 2.7.11.1 in 2004. 2.7.11.- is the generic level where all serine/threonine kinases should sit in.
=== Mass spectrometry === A mixture of 5-methoxysalicylic acid and spermine can be used as a matrix for oligonucleotides analysis in MALDI mass spectrometry. ElectroSpray Ionization Mass Spectrometry (ESI-MS) is also a powerful tool to characterize the mass of oligonucleotides.
Sources: en.wikipedia.org
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.
Mass spectrometry identifies molecules by mass-to-charge transitions, which reduces interference from related peptides. Immunoassays run faster but can cross-react. Structural confirmation usually requires the mass spectrometric approach.
Cardiovascular outcomes, long-term safety, and weight regain after stopping treatment are unresolved. These questions need years of follow-up data. Published evidence covers only limited treatment durations.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.